Literature DB >> 22554704

The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma.

Gregory A Hawkins1, Mac B Robinson, Annette T Hastie, Xingnan Li, Huashi Li, Wendy C Moore, Timothy D Howard, William W Busse, Serpil C Erzurum, Sally E Wenzel, Stephen P Peters, Deborah A Meyers, Eugene R Bleecker.   

Abstract

BACKGROUND: The IL6R single nucleotide polymorphism (SNP) rs4129267 has recently been identified as an asthma susceptibility locus in subjects of European ancestry but has not been characterized with respect to asthma severity. The SNP rs4129267 is in linkage disequilibrium (r(2) = 1) with the IL6R coding SNP rs2228145 (Asp(358)Ala). This IL6R coding change increases IL-6 receptor (IL-6R) shedding and promotes IL-6 transsignaling.
OBJECTIVES: We sought to evaluate the IL6R SNP rs2228145 with respect to asthma severity phenotypes.
METHODS: The IL6R SNP rs2228145 was evaluated in subjects of European ancestry with asthma from the Severe Asthma Research Program (SARP). Lung function associations were replicated in the Collaborative Study on the Genetics of Asthma (CSGA) cohort. Serum soluble IL-6R levels were measured in subjects from SARP. Immunohistochemistry was used to qualitatively evaluate IL-6R protein expression in bronchoalveolar lavage cells and endobronchial biopsies.
RESULTS: The minor C allele of IL6R SNP rs2228145 was associated with a lower percent predicted FEV(1) in the SARP cohort (P= .005), the CSGA cohort (P= .008), and in a combined cohort analysis (P= .003). Additional associations with percent predicted forced vital capacity (FVC), FEV(1)/FVC ratio, and PC(20) were observed. The rs2228145 C allele (Ala(358)) was more frequent in severe asthma phenotypic clusters. Elevated serum soluble IL-6R levels were associated with lower percent predicted FEV(1) (P= .02) and lower percent predicted FVC (P= .008) (n= 146). IL-6R protein expression was observed in bronchoalveolar lavage macrophages, airway epithelium, vascular endothelium, and airway smooth muscle.
CONCLUSIONS: The IL6R coding SNP rs2228145 (Asp(358)Ala) is a potential modifier of lung function in subjects with asthma and might identify subjects at risk for more severe asthma. IL-6 transsignaling might have a pathogenic role in the lung.
Copyright © 2012 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22554704      PMCID: PMC3409329          DOI: 10.1016/j.jaci.2012.03.018

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   14.290


  24 in total

Review 1.  Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

2.  Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists.

Authors:  Laure Brulhart; Michael J Nissen; Paola Chevallier; Cem Gabay
Journal:  Joint Bone Spine       Date:  2010-09-20       Impact factor: 4.929

3.  Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program.

Authors:  Wendy C Moore; Eugene R Bleecker; Douglas Curran-Everett; Serpil C Erzurum; Bill T Ameredes; Leonard Bacharier; William J Calhoun; Mario Castro; Kian Fan Chung; Melissa P Clark; Raed A Dweik; Anne M Fitzpatrick; Benjamin Gaston; Mark Hew; Iftikhar Hussain; Nizar N Jarjour; Elliot Israel; Bruce D Levy; James R Murphy; Stephen P Peters; W Gerald Teague; Deborah A Meyers; William W Busse; Sally E Wenzel
Journal:  J Allergy Clin Immunol       Date:  2007-02       Impact factor: 10.793

4.  Tocilizumab as a potential treatment in Schnitzler syndrome.

Authors:  Nicolas Kluger; Didier Bessis; Bernard Guillot
Journal:  Med Hypotheses       Date:  2009-01-17       Impact factor: 1.538

5.  Circulating levels of soluble interleukin-6 receptor in patients with bronchial asthma.

Authors:  A Yokoyama; N Kohno; K Sakai; K Kondo; Y Hirasawa; K Hiwada
Journal:  Am J Respir Crit Care Med       Date:  1997-11       Impact factor: 21.405

6.  Standardization of Spirometry, 1994 Update. American Thoracic Society.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1995-09       Impact factor: 21.405

7.  Ethnic differences in asthma and associated phenotypes: collaborative study on the genetics of asthma.

Authors:  L A Lester; S S Rich; M N Blumenthal; A Togias; S Murphy; F Malveaux; M E Miller; G M Dunston; J Solway; R L Wolf; J M Samet; D G Marsh; D A Meyers; C Ober; E R Bleecker
Journal:  J Allergy Clin Immunol       Date:  2001-09       Impact factor: 10.793

8.  Identification of IL6R and chromosome 11q13.5 as risk loci for asthma.

Authors:  Manuel A R Ferreira; Melanie C Matheson; David L Duffy; Guy B Marks; Jennie Hui; Peter Le Souëf; Patrick Danoy; Svetlana Baltic; Dale R Nyholt; Mark Jenkins; Catherine Hayden; Gonneke Willemsen; Wei Ang; Mikko Kuokkanen; John Beilby; Faang Cheah; Eco J C de Geus; Adaikalavan Ramasamy; Sailaja Vedantam; Veikko Salomaa; Pamela A Madden; Andrew C Heath; John L Hopper; Peter M Visscher; Bill Musk; Stephen R Leeder; Marjo-Riitta Jarvelin; Craig Pennell; Dorret I Boomsma; Joel N Hirschhorn; Haydn Walters; Nicholas G Martin; Alan James; Graham Jones; Michael J Abramson; Colin F Robertson; Shyamali C Dharmage; Matthew A Brown; Grant W Montgomery; Philip J Thompson
Journal:  Lancet       Date:  2011-09-10       Impact factor: 79.321

9.  Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE).

Authors:  Vance Matthews; Björn Schuster; Stefan Schütze; Ingo Bussmeyer; Andreas Ludwig; Christian Hundhausen; Thorsten Sadowski; Paul Saftig; Dieter Hartmann; Karl-Josef Kallen; Stefan Rose-John
Journal:  J Biol Chem       Date:  2003-06-27       Impact factor: 5.157

10.  Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.

Authors:  Hiroshi Kawabata; Naohisa Tomosugi; Junya Kanda; Yasuhiro Tanaka; Kazuyuki Yoshizaki; Takashi Uchiyama
Journal:  Haematologica       Date:  2007-06       Impact factor: 9.941

View more
  37 in total

1.  IL-6 receptor α defines effector memory CD8+ T cells producing Th2 cytokines and expanding in asthma.

Authors:  Naeun Lee; Sungyong You; Min Sun Shin; Won-Woo Lee; Ki Soo Kang; Sang Hyun Kim; Wan-Uk Kim; Robert J Homer; Min-Jong Kang; Ruth R Montgomery; Charles S Dela Cruz; Albert C Shaw; Patty J Lee; Geoffrey L Chupp; Daehee Hwang; Insoo Kang
Journal:  Am J Respir Crit Care Med       Date:  2014-12-15       Impact factor: 21.405

2.  IL-6 trans-signaling increases expression of airways disease genes in airway smooth muscle.

Authors:  Mac B Robinson; Deepak A Deshpande; Jeffery Chou; Wei Cui; Shelly Smith; Carl Langefeld; Annette T Hastie; Eugene R Bleecker; Gregory A Hawkins
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-05-22       Impact factor: 5.464

3.  A pilot study of single nucleotide polymorphisms in the interleukin-6 receptor and their effects on pre- and post-transplant serum mediator level and outcome after allogeneic stem cell transplantation.

Authors:  T H A Tvedt; R Hovland; G Tsykunova; A B Ahmed; T Gedde-Dahl; Ø Bruserud
Journal:  Clin Exp Immunol       Date:  2018-04-01       Impact factor: 4.330

4.  Arginine metabolic control of airway inflammation.

Authors:  Kewal Asosingh; Chris D Lauruschkat; Mario Alemagno; Matthew Frimel; Nicholas Wanner; Kelly Weiss; Sean Kessler; Deborah A Meyers; Carole Bennett; Weiling Xu; Serpil Erzurum
Journal:  JCI Insight       Date:  2020-01-30

5.  IL-6/STAT3 promotes regeneration of airway ciliated cells from basal stem cells.

Authors:  Tomomi Tadokoro; Yang Wang; Larry S Barak; Yushi Bai; Scott H Randell; Brigid L M Hogan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

6.  Investigation of the relationship between IL-6 and type 2 biomarkers in patients with severe asthma.

Authors:  Xingnan Li; Annette T Hastie; Michael C Peters; Gregory A Hawkins; Wanda Phipatanakul; Huashi Li; Wendy C Moore; William W Busse; Mario Castro; Serpil C Erzurum; Benjamin Gaston; Elliot Israel; Nizar N Jarjour; Bruce D Levy; Sally E Wenzel; Deborah A Meyers; John V Fahy; Eugene R Bleecker
Journal:  J Allergy Clin Immunol       Date:  2019-09-09       Impact factor: 10.793

7.  Treatment options in type-2 low asthma.

Authors:  Timothy S C Hinks; Stewart J Levine; Guy G Brusselle
Journal:  Eur Respir J       Date:  2021-01-21       Impact factor: 16.671

Review 8.  Severe Asthma in Children: Lessons Learned and Future Directions.

Authors:  Anne M Fitzpatrick
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Jan-Feb

Review 9.  Genetics of asthma susceptibility and severity.

Authors:  Rebecca E Slager; Gregory A Hawkins; Xingnan Li; Dirkje S Postma; Deborah A Meyers; Eugene R Bleecker
Journal:  Clin Chest Med       Date:  2012-07-07       Impact factor: 2.878

10.  Identification of STOML2 as a putative novel asthma risk gene associated with IL6R.

Authors:  J A Revez; M C Matheson; J Hui; S Baltic; A James; J W Upham; S Dharmage; P J Thompson; N G Martin; J L Hopper; M A R Ferreira
Journal:  Allergy       Date:  2016-03-24       Impact factor: 13.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.